Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference

WATERTOWN, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR®...
September 29, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions

WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR®...
September 12, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
September 06, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
August 04, 2022 07:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint...
August 01, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
July 28, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
July 06, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference

WATERTOWN, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
June 13, 2022 07:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates

-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- -Selecta to receive a $2 million payment from Sarepta...
May 17, 2022 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference

WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...